Celon Pharma (LTS:0RKX) Other Long-Term Liabilities: zł1.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RKX Celon Pharma SA LTS:0RKX
23 GF Score
Price zł22.50
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Other Long-Term Liabilities?

Celon Pharma LTS:0RKX 23 Other Long-Term Liabilities is zł1.2 Mil as of Mar. 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Celon Pharma's other long-term liabilities for the quarter that ended in Mar. 2026 was zł1.2 Mil.

Celon Pharma's quarterly other long-term liabilities increased from Sep. 2025 (zł0.9 Mil) to Dec. 2025 (zł30.9 Mil) but then declined from Dec. 2025 (zł30.9 Mil) to Mar. 2026 (zł1.2 Mil).

Celon Pharma's annual other long-term liabilities declined from Dec. 2023 (zł31.7 Mil) to Dec. 2024 (zł31.7 Mil) and declined from Dec. 2024 (zł31.7 Mil) to Dec. 2025 (zł30.9 Mil).

Celon Pharma Other Long-Term Liabilities Related Terms

Celon Pharma Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Other Long-Term Liabilities Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.63 39.29 31.71 31.69 30.95

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.44 1.01 0.93 30.95 1.21
LTS:0RKX
23GF Score
Celon Pharma SA LTS:0RKX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of zł1.2 Mil mean?
Celon Pharma (LTS:0RKX) has a Other Long-Term Liabilities of zł1.2 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Other Long-Term Liabilities too high?
Celon Pharma's current Other Long-Term Liabilities is zł1.2 Mil. Overall, Celon Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Other Long-Term Liabilities compare to ZTS and UTHR?
Celon Pharma's Other Long-Term Liabilities of zł1.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Celon Pharma and its competitors. Celon Pharma's current Other Long-Term Liabilities is zł1.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Other Long-Term Liabilities of zł1.2 Mil. The current Other Long-Term Liabilities is zł1.2 Mil. Celon Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Other Long-Term Liabilities is zł1.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celon Pharma Business Description

Other Exchanges CLN:Poland8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
23GF Score

Get the complete analysis for LTS:0RKX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł22.50
Price